Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Chlorthalidone Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study of the Impact of the Patient Activated Learning System (PALS) on Knowledge Acquisition, Recall, and Decision Making

NCT03156634
View directory record Official record
Conditions
Patient Education
Interventions
PALS, WebMD
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study

NCT02591628
View directory record Official record
Conditions
Hypertension
Interventions
HCTZ prescription conversion to chlorthalidone
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
2,027 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Bloomington, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Uric Acid and Hypertension in African Americans

NCT00241839
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions
Allopurinol, Placebo, Chlorthalidone, Potassium chloride
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension

NCT00818883
View directory record Official record
Conditions
Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil and hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
50
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Scottsboro, Alabama + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 4 Interventional

Diuretics and Volume Overload in Early CKD

NCT05171686
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Tissue Sodium in Pre-hypertensive Patients

NCT02236520
View directory record Official record
Conditions
Hypertension
Interventions
Spironolactone, Chlorthalidone, Diet, Placebo
Drug · Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
50 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium

NCT02711670
View directory record Official record
Conditions
Kidney Stones
Interventions
chlorthalidone, Hydrochlorothiazide
Drug
Lead sponsor
VA New York Harbor Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 23, 2026, 4:32 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

NCT02232880
View directory record Official record
Conditions
Hypertension
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

NCT00695955
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Ozark, Alabama • Tallassee, Alabama • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 23, 2026, 4:32 AM EDT
Not yet recruiting Phase 2 Interventional

LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial

NCT07645300
View directory record Official record
Conditions
Hypertension Treated With Antihypertensive Drugs, Chronic Kidney Disease, 3B and 4
Interventions
phase 2A Chlorthalidone, phase 2A Spironolactone, phase 2A Chlorthalidone + Spironolactone, phase 2B Chlorthalidone LD + Spironolactone LD
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension

NCT00591773
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Chlorthalidone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
46
States / cities
Huntsville, Alabama • Montgomery, Alabama • Buena Park, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 23, 2026, 4:32 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Chlorthalidone in Type 1 Diabetes

NCT03325114
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypercalciuria
Interventions
Chlorthalidone
Drug
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 23, 2026, 4:32 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Hypertension in Young Adults Trial

NCT05370599
View directory record Official record
Conditions
Hypertension
Interventions
Anti-hypertensive agent: amlodipine, Anti-hypertensive agent: Chlorthalidone, Anti-hypertensive agent: Losartan, Home BP monitoring with cuffed device, Home BP monitoring with cuffed device + BP patch, Home BP monitoring with cuffed device + BP watch
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 23, 2026, 4:32 AM EDT
Withdrawn Phase 4 Interventional

Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)

NCT05275907
View directory record Official record
Conditions
High Blood Pressure, Liver Transplant, Renal Function Abnormal
Interventions
Amlodipine Besylate, Chlorthalidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 23, 2026, 4:32 AM EDT
Withdrawn Phase 4 Interventional

EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network

NCT01748123
View directory record Official record
Conditions
Hypertension
Interventions
Chlorthalidone, Hydrochlorothiazide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Early Phase 1 Interventional

Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension.

NCT06287580
View directory record Official record
Conditions
Essential Hypertension, Older Adults
Interventions
chlorthalidone, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Results available

Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity

NCT04519164
View directory record Official record
Conditions
Metabolic Syndrome, Hypertension, Overweight and Obesity
Interventions
Eplerenone, Chlorthalidone with potassium chloride
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 4:32 AM EDT
Not listed Phase 2 Interventional

Spironolactone in CKD Enabled by Chlorthalidone: PILOT

NCT05222191
View directory record Official record
Conditions
Renal Insufficiency, Chronic Hypertension
Interventions
Spironolactone, Chlorthalidone, Placebo
Drug
Lead sponsor
Indiana Institute for Medical Research
Other
Eligibility
19 Years to 110 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 23, 2026, 4:32 AM EDT
Withdrawn Phase 4 Interventional

Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function

NCT01822860
View directory record Official record
Conditions
Hypertension
Interventions
Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Placebo
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 23, 2026, 4:32 AM EDT
Recruiting Phase 4 Interventional

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

NCT05593055
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy
Interventions
Eplerenone, Chlorthalidone, Potassium
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Diuretic Comparison Project

NCT02185417
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide (HCTZ), Chlorthalidone (CTD)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
20,723 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
69
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 23, 2026, 4:32 AM EDT